Integral Molecular, the industry leader in the discovery and engineering of antibodies against membrane proteins, announces ...
Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...
Artists Earn a $1,000 Stipend While Inspiring Drug DiscoveryMADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer ...
The open-label, multi-center Phase â…¡ clinical study is led by Professor Shen Lin of Beijing Cancer Hospital and is being conducted across multiple hospitals in China. The trial aims to evaluate the ...
UAB researchers discover that the immune system consistently targets the same region of mismatched HLA proteins after organ ...
Lead author Patricia LoRusso, DO, PhD (hc), FAACR will present an updated data cut from the late breaking abstract on Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST). The ...
In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, ...
Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced it will present new preclinical data demonstrating that DRG5--BD11, a novel human bispecific ...
First-in-human study of EPI-326 will evaluate the company's lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to expand to CRC AACR 2026 presentations, including New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results